Metabolic involvement in adriamycin cardiotoxicity

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Adriamycin (doxorubicin) is a widely used chemotherapy agent with known cardiotoxic side effects.
• The precise mechanisms underlying adriamycin-induced cardiotoxicity are not fully understood, but energy metabolism disruption is suspected.
• Mammalian myocardial cells in culture serve as a valuable model system for studying drug effects on heart cells.

Purpose of the Study:

• To investigate the cardiotoxic effects of adriamycin on mammalian myocardial cells in culture.
• To elucidate the role of energy metabolism in adriamycin-induced cardiotoxicity.
• To explore the potential of adenosine as a protective agent against adriamycin cardiotoxicity.

Main Methods:

• Cultured mammalian myocardial cells were treated with adriamycin.
• Cell growth and contractile activity were monitored.
• Adenylate energy charge and phosphorylcreatine mole fraction were measured.
• The effects of adenosine supplementation on adriamycin-treated cells were assessed.

Main Results:

• Adriamycin significantly inhibited myocardial cell growth and rhythmic contractions.
• A marked decrease in adenylate energy charge was observed in adriamycin-treated cells.
• The phosphorylcreatine mole fraction remained unchanged, suggesting creatine phosphokinase inhibition.
• Addition of adenosine restored adenylate energy charge and maintained cell functional integrity.

Conclusions:

• Adriamycin cardiotoxicity involves the disruption of cellular energy metabolism, specifically affecting adenylate energy charge.
• Inhibition of creatine phosphokinase may play a role in adriamycin's cardiotoxic mechanism.
• Adenosine supplementation demonstrates a protective effect, preserving myocardial cell function against adriamycin-induced damage.